MODERN PATHOLOGY

Research Article

The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer

Shorouk Makhlouf[a,b], Maryam Althobiti[c], Michael Toss[a,d], Abir A. Muftah[e],
Nigel P. Mongan[f,g], Andrew H.S. Lee[h], Andrew R. Green[a], Emad A. Rakha[a,h,i,*]

[a] Nottingham Breast Cancer Research Centre, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom;
[b] Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt; [c] Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia; [d] Department of Histopathology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom; [e] Department of Pathology, Faculty of Medicine, University of Benghazi, Benghazi, Libya; [f] Biodiscovery Institute, School of Veterinary Medicine and Sciences, University of Nottingham, Nottingham, United Kingdom;
[g] Department of Pharmacology, Weill Cornell Medicine, New York, New York; [h] Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; [i] Department of Pathology, Hamad Medical Corporation, Doha, Qatar

ARTICLE INFO

ABSTRACT

Estrogen receptor (ER) status in breast cancer (BC) is determined using immunohistochemistry (IHC) with nuclear expression in $\geq$1% of cells defined as ER-positive. BC with 1%-9% expression (ER-low-positive), is a clinically and biologically unique subgroup. In this study, we hypothesized that ER-low-positive BC represents a heterogeneous group with a mixture of ER-positive and ER-negative tumor, which may explain their divergent clinical behavior. A large BC cohort (n = 8171) was investigated and categorized into 3 groups: ER-low-positive (1%-9%), ER-positive ($\geq$10%), and ER-negative (<1%) where clinicopathological and outcome characteristics were compared. A subset of ER-low-positive cases was further evaluated using IHC, RNAscope, and RT-qPCR. PAM50 subtyping and *ESR1* mRNA expression levels were assessed in ER-low-positive cases within The Cancer Genome Atlas data set. The reliability of image analysis software in assessment of ER expression in the ER-low-positive category was also assessed. ER-low-positive tumors constituted <2% of BC cases examined and showed significant clinicopathological similarity to ER-negative tumors. Most of these tumors were nonluminal types showing low *ESR1* mRNA expression. Further validation of ER status revealed that 45% of these tumors were ER-negative with repeated IHC staining and confirmed by RNAscope and RT-qPCR. ER-low-positive tumors diagnosed on needle core biopsy were enriched with false-positive ER staining. BCs with 10% ER behaved similar to ER-positive, rather than ER-negative or low-positive BCs. Moderate concordance was found in assessment of ER-low-positive tumors, and this was not improved by image analysis. Routinely diagnosed ER-low-positive BC includes a proportion of ER-negative cases. We recommend repeat testing of BC showing 1%-9% ER expression and using a cutoff $\geq$10% expression to define ER positivity to help better inform treatment decisions.

Introduction

Estrogen receptor (ER) is a key oncogenic driver in the majority of breast cancer (BC) and is expressed in about 80% of BC.[1] It is an established prognostic and predictive biomarker for BC

* Corresponding author.
  E-mail address: emad.rakha@nottingham.ac.uk (E.A. Rakha).

management decision making.[2] In the clinical setting, BC with ER immunohistochemical (IHC) expression in ≥1% of nuclei of invasive tumor cells is considered ER-positive for endocrine therapy (ET) eligibility.[3,4] However, ER shows significant intra-tumoral heterogeneity and there remains evidence that ER expression levels are linearly correlated with ET response.[5] Although ET significantly improves the overall survival of patients with ER-positive BC, the ER-threshold for response to ET is uncertain and the eligibility of those with low ER expression levels to adjuvant ET and chemotherapy is still debated.[6,7]

Historically, ER was assessed with ligand-binding assays. Meta-analysis of randomized trials showed that tamoxifen was beneficial where ER expression was as low as 10−19 fmol/mg cytosol protein.[8] However, there have been no large trials of ET in the context of the more widely used IHC assessment of ER expression. The 1% cutoff proposed for ER was proposed to be functionally equivalent to 10 fmol/mg cytosol protein as measured by ligand-binding assays. The management of BC with low ER expression levels remains a challenge in routine practice, and there is debate about whether BCs with low ER expression differ from ER-negative tumors. It is argued that patients with low ER tumors benefit from chemotherapy and most of them have overlapping genetic profiles with ER-negative tumors.[9,10]

The latest American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) guidelines update for ER and progesterone receptor (PR) testing in BC[11] recommend that tumors with low ER expression levels (1%-10%) be reported as "ER-low-positive" along with a comment about inadequate evidence of ET benefit. In these guidelines, not only tumors with 10% were considered ER-low-positive, but also the requirement for repeat testing was limited to cases with a suspected analytical issue. Other measures include the use of validated quantitative digital image analysis to confirm interpretation.[11] The definition of ER-low expression also differs in literature from 1% to 9%[7,12-14] or 1% to 10%.[15-18]

ER status is assessed in the clinical setting utilizing needle core biopsy (NCB), and it is repeated on surgical excision specimens in a limited number of cases.[3,4] One challenge in designating the ER status of BC tumor, particularly those with low ER expression in NCB, is the specificity and reproducibility of assessment in a limited tissue sample. Discrimination between false and true IHC staining is often challenging and requires strict adherence to high-quality standards to minimize subjective factors influencing assessment.

We hypothesized that BC with ER-low-positive expression as assessed on NCB are biologically and clinically heterogeneous and behave differently compared to tumors with higher ER expression, as a considerable percentage of these tumors are falsely interpreted as ER-positive. We thus aimed to (1) characterize ER-low-positive BC, as assessed on NCB, with an emphasis on its prevalence and association with different clinicopathological parameters and patient outcome using a large well-characterized BC cohort, (2) evaluate the spectrum of ER IHC staining using different techniques to distinguish ER-positive from ER-negative and to identify the proportion of cases remaining as ER-low-positive, (3) identify the optimal cutoff to distinguish ER-low-positive BC from ER-positive BC, and (4) determine the value of image analysis in tumors showing low ER expression to provide improved pathological assessment.

Materials and Methods

This study included 2 cohorts, the Nottingham Cohort (n = 8171), and The Cancer Genome Atlas (TCGA) BC cohort (n = 1047).

Nottingham Cohort

A large cohort of patients with primary invasive BC presented to Nottingham City Hospital, Nottingham, United Kingdom, from 1990 to 2018 was investigated, where relevant clinicopathological data of 7559 cases was available. Clinico-pathological data including age at diagnosis, tumor histologic grade and its components, tumor size, histologic tumor type, ER, PR, human epidermal growth factor receptor 2 (HER2) status, Ki67 index,[19] lymph node stage, lymphovascular invasion, and Nottingham Prognostic Index (NPI) were collected. Hormonal receptors and HER2 were assessed in accordance with published guidelines.[11,20] Receptors were assessed on the NCBs as part of the routine patient health care. ER positivity between 1% and 9% of invasive tumor cells represented 1.6% of cases (n = 123). Supplementary Figure S1 illustrates the Nottingham Cohort characteristics. Although the Nottingham protocol for tissue processing of excision specimens ensured adequate fixation as demonstrated by the biomarkers' staining quality in previous publications,[21-24] it was decided to further validate the ER expression level in the excision specimens using (1) IHC with 2 different antibody clones with and without casein blocking, (2) *ESR1* mRNA expression using RNAscope, and (3) real-time reverse transcription-PCR (RT-qPCR). None of the patients included in this study received neoadjuvant therapy.

Immunohistochemical Staining

The available formalin-fixed paraffin-embedded (FFPE) tissue blocks from NCB and excisional biopsies of 64 cases initially reported as ER-low-positive BC were retrieved. In addition, a subset of cases (n = 39) with ER staining between 10% and 30% were used for comparison. Fresh hematoxylin and eosin sections were prepared from the specimens. Excision specimens were further reviewed to select sections containing the largest tumor burden, for repeated staining. Sections were cut at 4-μm thickness. IHC was carried out according to the standard in-house protocols. The slides were processed through prediluted Tris-based buffer with a basic pH (Roche) for 64 minutes at 95 °C for antigen retrieval. Either anti-ER Rabbit monoclonal antibody, SP1 clone, (Roche), or EP1 anti-ER Rabbit monoclonal antibody (Dako, Ref-M3643), based on availability, was applied and incubated for 16 and 30 minutes, respectively. A small subset of cases was also stained individually with both ER antibody clones (EP1 and SP1). In addition, casein block (Roche, antibody diluent with casein) was also tested in a subset of slides to evaluate whether casein blocking could refine the scoring and differentiate false-positive cases from true-positive cases. External (a known ER−high-positive BC case) and internal (normal breast ductal epithelial cells) controls were used.

Estrogen Receptor Expression Scoring

Available original ER IHC-stained slides in clinical settings were collected and reassessed by a pathologist (observer 1) and in case of discordance with the original reports, the case was independently assessed by another pathologist, and the agreed scoring was used in the final analysis. In addition, all old and newly stained slides were independently scored by a consultant breast pathologist (observer 2) with >20 years of experience to assess the overall concordance. Where blocks or slides were

unavailable, the score assigned at the initial assessment was used. The percentage of nuclear ER immunostaining, intensity, pattern (homogenous, granular (punctate) or mixed), subcellular localization, stromal, and background staining were evaluated. Intensities ranged from very weak to strong staining, using the internal (if present) or external positive controls as a benchmark.

Assessment of ESR1 mRNA Expression Level Using RNAscope and RT-qPCR

ESR1 mRNA expression was evaluated using RNAscope.[25] For each case, *ESR*, *PPIB* (positive control), and *DapB* (negative control) were tested. Additionally, for each run the following controls obtained from Advanced Cell Diagnostics (ACD, Bio-Techne Ltd) were employed: (1) HeLa cell pellets were used as assay controls to confirm inter-run consistency, (2) ACD triple-negative BC (TNBC) sample as an ER-negative control, and (3) ACD BC tissue as an ER-positive control. Briefly, tissue sections of 4-μm thickness were deparaffinized and dehydrated. The slides were incubated in pretreat 1 (ready-to-use endogenous blocker) followed by boiling pretreat 2 (citrate buffer 10 nmol/L, pH 6) for 15 minutes. Then, pretreat 3 (10 g/mL protease, Sigma−Aldrich) was added and incubated at 40 °C for 30 minutes in a HybEZ hybridization oven. Subsequently, in the hybridization step, the tissue was placed at 40 °C with the following solutions: target probes in hybridization buffer A [6X SSC (1X SSC is 0.15 mol/L NaCl, 0.015 mol/L Na-citrate), formamide 25%, 0.2% lithium dodecyl sulfate, blocking reagents] for 3 hours; preamplifier (2 nmol/L) in hybridization buffer B (20% formamide, $5\times$ SSC, 0.3% lithium dodecyl sulfate, 10% dextran sulfate, blocking reagents) for 30 minutes; amplifier (2 nmol/L) in hybridization buffer B for 15 minutes at 40 °C; and label probe (2 nmol/L) for 15 minutes in hybridization buffer C ($5\times$ SSC, 0.3% lithium dodecyl sulfate, blocking reagents). Signals were detected using a Fast Red chromogen, which was followed by hematoxylin counterstaining. RNAscope semi-quantitative scoring was based on the average number of signal dots detected per invasive tumor cell throughout the entire slide as follows: negative= 0−1 dot/tumor cell or 2−3 dots/tumor cell in <50% of tumor cells, 1 = 2−3 dots/tumor cell in >50% of tumor cells, 2 = 4−10 dots/tumor cell, 3 = >10 dots/tumor cell in >50% of tumor cells, and 4 = >10 dots/tumor cell in >50% of tumor cells with clusters of the signal[26] (Supplementary Fig. S2).

Real-time reverse-transcription-PCR

RNA was purified from FFPE tissue sections using RNeasy FFPE Kit (Qiagen), according to manufacturer's instructions. To assess RNA quantity and purity a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc) was used. Appropriate *ESR1* primers were designed by using PubMed and the Primer 3 software (web version 4.0.0) http://primer3.ut.ee/ (forward primer: TGGGCTTACTGACCAACCTG, reverse primer: CCTGATCATGGAGGGTCAAA). Complementary deoxyribonucleic acid (cDNA) was synthesized by reverse transcription of RNA, with reverse transcriptase (RT)+ and RT− reactions for every sample. After adding 2.5 μL of 0.5 μg random hexamers (Thermo Scientific 50142, 200 ng/μL) to 1 μg RNA, the samples were made up to a total volume of 15 μL of H_2O and were incubated at 70 °C for 5 minutes. Samples were

immediately placed on ice for 5 minutes and then centrifuged. A master mix was prepared as follows: 5 μL M-MLV RT Buffer 5X (Promega), 1.25 μL dNTP (10 mM) (Thermo Scientific), 1 μL M-MLV Reverse Transcriptase (Promega 200 U/μL), and 5.25 Lwater. Ten microliters of appropriate master mix was added to each sample to reach the total volume of 25 μL. Next, samples were incubated at 37 °C for 1 hour followed by 95 °C for 10 minutes. After that, samples were diluted 1:10 and stored at −20 °C. RT-negative samples in which RNase-free water was included instead of reverse transcriptase enzyme were prepared to ensure the purity of the RNA extracted sample from remains of genomic DNA.

RT-qPCR was analyzed using comparative ΔΔCt method, which quantifies RNA expression in the sample relative to a reference sample.[27] The cutoff point was selected depending on the average of the fold changes of negative cases relative to the pooled calibrator of negative ER expression cases. The cutoff point was 1.00 (1.006 ± 0.100).

Image Analysis

A subset of cases (n = 98) were assessed using QuPath software version 0.3.2/[28] The slides were scanned as high-resolution digital images at $20\times$ magnification using a 3D Histech Panoramic 250 Flash II scanner (3DHISTECH Ltd). Images were imported into QuPath, tumor areas were manually annotated, and positive cell detection command was applied (Supplementary Fig. S3). Cell detection settings were followed as Berben et al,[29] several parameters have been explored for setting optimal thresholds. Hematoxylin optical density was selected, a single intensity threshold was chosen and set at 0.1 and maximum background intensity was set to 2. The percentage of positive tumor cells detected divided by the overall tumor cell detection was considered. Scoring was carried out blindly and compared with visual estimates.

The Cancer Genome Atlas BC data set analysis

A BC cohort of publicly available TCGA data (n = 1047) with available ER data were used to identify *ESR1* mRNA expression and PAM50 subtyping of ER-low positive in comparison with higher ER expression. ER percentages were available as categories and ER IHC categories of 1%-9% (n = 17) and 10%-19% (n = 25) were analyzed. *ESR1* mRNA Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values were used and divided into quartiles for descriptive purposes.

Statistical Analysis

Statistical Package for the Social Sciences v26 for Windows was used. χ^2 test was used to compare categorical groups, while Mann−Whitney test was used for continuous variables. Interobserver agreement was determined using the intra-class correlation coefficient (ICC). Kaplan−Meier curves and log-rank test were used for survival analysis including BC-specific survival (BCSS) as time from initial diagnosis to death related to BC, distant metastasis−free survival (DMFS) defined as time from initial diagnosis to date of DM, and disease-free survival (DFS), which describes length of time to any recurrence event of disease. A *P*-value of less than .05 (2-tailed) was considered significant in all the statistical tests.

Table 1
Clinicopathological characteristics of ER 1%-9% in comparison other groups

Characteristics	ER immunohistochemical expression in needle core biopsies				
	ER 1%-9%	ER-negative	χ^2 (P value) [a]	ER $\geq$10%	χ^2 (P value) [b]
Age at diagnosis (y)					
<50	41 (33%)	547 (36%)	.2	1379 (23%)	6.7
$\geq$50	82 (67%)	985 (64%)	(.5)	4525 (77%)	(.01)[c]
Tumor size (cm)					
<2	58 (47%)	749 (49%)	.1	3888 (66%)	18.6
$\geq$2	65 (53%)	781 (51%)	(.7)	2016 (34%)	(<.001) [c]
Tumor grade					
1	4 (3%)	30 (2%)		1242 (21%)	
2	23 (20%)	202 (13%)	5.7	3097 (53%)	142.6
3	88 (77%)	1300 (85%)	(.05)	1564 (26%)	(<.001) [c]
Mitotic count					
1	19 (16%)	168 (11%)		3848 (65%)	
2	34 (30%)	285 (19%)	13.7	1038 (18%)	135.3
3	62 (54%)	1079 (70%)	(.001)[c]	1017 (17%)	(<.001) [c]
Nuclear pleomorphism					
1	2 (2%)	12 (1%)		110 (2%)	
2	11 (9%)	76 (5%)	5.7	2814 (48%)	67.1
3	102 (89%)	1444 (94%)	(.05)	2979 (50%)	(<.001)[c]
Tubule formation					
1	2 (2%)	14 (1%)		554 (9%)	
2	21 (18%)	244 (15%)	1.9	1776 (30%)	19.4
3	92 (80%)	1294 (84%)	(.3)	3573 (61%)	(<.001)[c]
Nottingham Prognostic Index					
Good prognostic group	10 (9%)	135 (9%)		2830 (48%)	
Moderate prognostic group	82 (73%)	1037 (68%)	1.4	2493 (42%)	67.7
Poor prognostic group	20 (18%)	345 (23%)	(.4)	564 (10%)	(<.001)[c]
Histologic types					
No special type (NST)	100 (87%)	1381 (90%)		3357 (57%)	
Lobular	4 (3%)	31 (2%)		802 (13%)	
Other special types	3 (3%)	57 (4%)	3.6	392 (7%)	41.9
Mixed NST and other tumor types	8 (7%)	63 (4%)	(.3)	1352 (23%)	(<.001)[c]
Axillary nodal status					
Negative	74 (66%)	961 (63%)	.2	3986 (68%)	.24
Positive	39 (34%)	558 (37%)	(.6)	1902 (32%)	(.6)
Lymph node stage					
1 (Negative)	74 (65%)	961 (63%)		3986 (68%)	
2 (1−3 positive)	28 (25%)	378 (25%)	.4	1532 (26%)	2.2
3 (>3 positive)	11 (10%)	180 (12%)	(.7)	370 (6%)	(.3)
Lymphovascular invasion					
Negative	94 (83%)	1108 (72%)	6.3	4706 (80%)	.81
Positive	19 (17%)	424 (28%)	(.01)[c]	1196 (20%)	(.3)
Progesterone receptor					
Negative	82 (82%)	1392 (98%)	77.2	1086 (19%)	241.2
Positive	18 (18%)	30 (2%)	(<.001)[c]	4599 (81%)	(<.001) [c]
HER2 status					
Negative	72 (69%)	1044 (73%)	.8	5107 (91%)	54.2
Positive	33 (31%)	380 (27%)	(.3)	532 (9%)	(<.001) [c]
Ki67 index					
Low ($\leq$14%)	3 (14%)	121 (18%)	0.1	1417 (57%)	15.7
High (>14%)	18 (86%)	566 (82%)	(0.6)	1058 (43%)	(<.001) [c]

ER, estrogen receptor.
[a] ER 1%−9% vs ER-negative.
[b] ER 1%−9% vs ER $\geq$ 10%.
[c] P values are considered to be significant.

Results

ER-positive tumors ($\geq$1%) represented 78% of the Nottingham Cohort including 123 cases (1.6%) which were initially reported as ER-low-positive (1%-9%) based on NCB assessment in the clinical setting. The median percentage of ER positivity in the 1%-9% group was 4% (mean: 3.6±1.9%). 167 cases had ER expression in 10%-30%.

Clinicopathological Characteristics of ER-Low-Positive BC

Most of the clinicopathological parameters of tumors initially reported as ER-low-positive (1%-9%) were similar to the ER-negative tumors but showed significant differences compared with ER-positive tumors ($\geq$10%) in most clinicopathological parameters (Table 1). When ER 1%-9% BCs were compared with the

tumors showing ER expression in 10%-30% of the cells, they were more often of higher grade, larger in size, and showed higher NPI, higher Ki67 index, and were more likely to be PR negative and HER2 positive (Supplementary Table S1).

Outcome Analysis

Compared with ER-negative patients, the ER 1%-9% group showed no differences in BCSS, DMFS, or DFS ($P = .9$, $P = .3$, and $P = .2$, respectively) despite the difference in ET given. In contrast, ER 1%-9% showed significantly shorter BCSS compared with patients with ER-positive ≥10% BC ($P = .002$) (Supplementary Fig. S4).

Breast Cancer with 10% ER Expression

As the number of cases scored as 10% ER was relatively high (n = 47), considering the lack of consensus regarding 10% as ER-low-positive or ER-positive, we next repeated the analysis considering tumors with 1%-10% as ER-low-positive cases. ER-low-positive group (1%-10%) showed lower tumor grade and grade components compared with ER-negative tumors (Supplementary Table S2). Outcome analysis revealed that patients with ER 1%-10% had both longer DMFS and DFS compared with ER-negative patients ($P = .03$ and $P = .02$, respectively) (Fig. 1).

As a group, tumors with 10% ER expression were significantly lower grade, better NPI, and more PR positive than tumors with ER 1%-9%, whereas they did not show a significant difference from tumors with ER 11%-30% (Supplementary Table S3). BCs with ER

10% have not shown significant outcome difference from patients with ER 11%-30% BC.

ESR1 mRNA Expression and PAM50 Classification

The association between the ER protein expression and *ESR1* mRNA expression obtained from the TCGA−BRCA study revealed no difference in *ESR1* mRNA expression and PAM50 molecular subtypes between ER-negative and ER 1%-9% ($P = .1$ and $P = .2$, respectively). ER 1%-9% had significantly lower *ESR1* mRNA expression than the ER 10%-19% group ($P = .005$) and a significant difference in PAM50 classification ($P = .007$). Supplementary Tables S4 and S5 show *ESR1* and PAM50 classification of each ER category. The ER-negative group had *ESR1* expression in the lower quartile in 92% of cases. ER, 1%-9% cases showed lower quartile expression in 59% of cases compared to only 20% of 10%-19%. ER-negative tumors showed nonluminal molecular profiling in 94% of cases compared with 81% of the 1%-9% group, whereas the 10%-19% group predominantly expressed luminal subtyping (76%).

Validation of ER-Low-Positive Expression

In the 64 originally reported ER-low-positive group (1%-9%), 30 cases (47%) were negative on repeated IHC staining on the excisional specimens (Fig. 2), 16 cases remained in the ER 1%-9% group, whereas 18 were more strongly positive (≥10%) (Supplementary Fig. S5). After re-staining, RNAscope was also negative in 82% of negative cases in addition to RT-qPCR, which yielded the same result. All these cases were also PR-negative. Among cases that


Figure 1.
Kaplan−Meier survival plots of ER-low-positive and ER-negative breast cancers (BCs). (A) Distant metastasis−free survival (DMFS) plot showing the insignificant difference between patients with ER-low-positive (1%-9%) BC (n = 20) and patients who were ER-negative (n = 611). (B) DMFS plot showing significant difference between patients with ER 1%-10% (n = 35) and ER-negative (n = 611). (C) Disease-free survival (DFS) plot showing insignificant difference between patients with ER (1%-9%; n = 20) BC and ER-negative (n = 611). (D) DFS plot showing significant difference between patients with ER (1%-10%; n = 35) BC and ER-negative (n = 611). ER, estrogen receptor

Figure 2.
Example of needle core biopsy with paired surgical excision specimen`s immunohistochemistry and RNAscope. (A, B) Core biopsy with low estrogen receptor expression (8%) (20× and 40× magnification), (C) negative immunohistochemistry excision specimen, and (D) negative RNAscope. (C, D, ×20 magnification).

remained positive, RNAscope confirmed positivity by 93% and RT-qPCR was positive in 64% of cases tested. Most of these cases (71%) were PR-negative.

Of the ER-positive cases (10%-30%), RNAscope was positive in all cases, whereas RT-qPCR was negative in 20% of cases. In that group (ER 10%-30%), PR was positive in 32% of cases. In the subset of cases that have been initially reported as 10%, positive expression was present in 70% when repeated (Tables 2 and 3).

Staining Patterns

In 64% of cases, an unusual staining pattern of ER was observed, which was characterized by very weak-to-weak granular/punctate staining that was mostly associated with nonspecific staining either cytoplasmic or background staining (Fig. 3). In ER 1%-9% cases, 56% of cases with the unusual pattern were negative on the repeat (Supplementary Fig. S6). Cases of ER 10%-30% that showed negative ER status on repeat displayed the same staining pattern in the NCB (Supplementary Fig. S7). Regarding the staining intensity, 72% of ER-low-positive cases showed very weak-to-weak

intensity. Over half of the cases (56%) showed nonspecific staining: stromal (34%), cytoplasmic (29%), both stromal and cytoplasmic (25%) or background nonspecific staining (12%) (Supplementary Fig. S8).

Comparison Between Different ER Antibody Clones

There was strong agreement in assessment between different ER antibody clones tested (ICC = 0.98). Cases with unusual granular staining pattern did not show differences using both clones. When the casein block step was employed in IHC, nonspecific staining was reduced in 66% of cases and these cases showed a high concordance between observers (ICC = 0.88). However, some of the true-positive but weak intensity ER staining (40%) were classed as ER-negative when the casein blocking step was used. Therefore, casein was not used in the remaining cases to differentiate true from false staining (Supplementary Fig. S9).

Concordance in ER-Low-Positive Staining Assessment

The concordance between the 3 pathologists' visual scoring (observers 1 and 2, in addition to the original clinical scoring retrieved from reports) was assessed and revealed moderate agreement (ICC = 0.5). Furthermore, the same level of agreement was observed between visual estimate and QuPath scoring (ICC = 0.5). The highly discordant cases were associated with either background cytoplasmic staining that was considered positive by QuPath or very weak staining that was not detected as positive cells by QuPath. Contrasting this, when ER-positive cases (>50% ER positivity) (n = 40) were used for calibration, excellent concordance (ICC = 0.9) was obtained.

Table 2
Comparison of the initial and repeated ER immunohistochemical expression

Initial core biopsy	Repeated ER staining			Total
	Negative (<1%)	Low-positive (1%-9%)	Positive (≥10%)	
ER 1%-9%	30 (47%)	16 (25%)	18 (28%)	64
ER 10%	3 (30%)	2 (20%)	5 (50%)	10
ER 11%-30%	11 (38%)	4 (14%)	14 (48%)	29

ER, estrogen receptor.

Table 3

Comparison of the initial and repeated ER immunohistochemical expression, RNAscope, and RT-PCR

Initial core biopsy	RNAscope		Total	RT-qPCR		
	Negative	Positive		Negative	Positive	Total
ER 1%-9% and ER-negative on repeat	9 (82%)	2 (18%)	11	9 (82%)	2 (18%)	11
ER 1%-9% and ER-positive on repeat	1 (7%)	14 (93%)	15	4 (36%)	7 (64%)	11
ER 10%-30% and ER-negative on repeat	2 (67%)	1 (33%)	3	3 (100%)	0	3
ER 10%-30% and ER-positive on repeat	0	10 (100%)	10	2 (20%)	8 (80%)	10

ER, estrogen receptor.

Discussion

The ER expression has largely been considered a binary variable where ER is either expressed or not. This simplified dichotomization of ER expression facilitates patient risk stratification and therapeutic management. However, semiquantitative rather than qualitative assessment of ER has a confounding impact on treatment strategy as the threshold for response to ET remains uncertain.[5] The ASCO/CAP guidelines defining ER positivity as low as 1% has led to those tumors expressing ER at low levels being considered as "ER-low-positive BC." However, whether the ER-low group represents a distinct entity as opposed to either true ER positive or ER-negative remains uncertain. This can either deprive patients from receiving chemotherapeutic agents, probable benefit from ET, or combination therapies.[30,31] Moreover, several issues relating to ER-low-positive BC remain to be addressed including whether these ER-low tumors more closely resembling ER-negative are related to being low but genuine expressers or a mixture of both ER-positive and ER-negative tumors. ER-low-positive tumors in a limited NCB could represent the low percentage (<1%) of ER-stained cells in higher tumor cellularity of an excisional specimen or due to enrichment with false-positive ER staining. Indeed, it remains uncertain whether cases with 10% ER expression should be included in the ER-low-positive or ER-

Figure 3.
(A−D) Examples of unusual estrogen receptor staining patterns with very weak-to-weak granular staining. (×100 magnification). (E, F) Diagram showing the difference between (E) homogenous staining pattern and (F) unusual staining pattern with very weak granular nuclear staining.

positive category. The benefits of image analysis as a reliable tool to assess such cases more accurately than a pathologist's visual estimate is also yet to be established.

To address these challenges, we used a large cohort to define the prevalence and clinicopathological characteristics of the ER-low category. Less than 2% of cases were ER-low-positive. Previous reports have demonstrated a wide range in prevalence (<2% up to 9%) of ER-low cases in cohorts.[2,32-34] Consistent with previous reports,[2,10,33,34] we found that most clinicopathological criteria and outcomes of ER-low-positive tumors were similar to ER-negative BC. Although the ER-low-positive group showed higher PR positivity than the ER-negative tumors, PR was negative in cases that were ER-negative following validation and repeat ER staining. PR is thought to be mainly regulated by ER through binding to the *PgR* promotor region.[35]

Previous studies investigated the molecular subtyping of ER-low-positive BC where >80% were either basal-like or HER2 enriched.[9,13,36] Although this may be the result of low ER protein expression and inactive downstream ER pathways, our study demonstrated by repeating ER IHC staining and validation using *ESR1* gene expression levels that a large proportion should be classified as ER-negative if strict criteria for ER assessment were used. The basis for false-positive ER staining in NCBs in ER-low-positive tumors were multifactorial and related to the weak intensity and unusual pattern of staining. A few cases were reassigned into the ER-negative (<1%) category due to the difference in the percentage of positive cells between NCB and the excision specimen, and these were negative at the mRNA level. Importantly, ER-low-positive tumors assessed on NCB which remained ER-low-positive/positive showed a higher frequency of PR positivity and clinicopathological features that are different from ER-negative tumors. Therefore, we suggest repeating ER IHC staining in all ER-low-positive tumors before assigning them as either ER-negative or ER-positive, unlike the ASCO/CAP recommendation, which limits repeat ER staining to cases with preanalytical/analytical issues.[11] The observed weak granular staining pattern of ER was difficult to interpret. This unusual pattern showed a high probability of negativity on re-staining, even with cases showing higher ER expression (10%-30%). These staining patterns can be identified by pathologists as clues for false-positive staining, therefore we suggest reporting weak granular staining as ER-positive with a caveat that it may represent false-positive staining and recommend repeating staining on excisional specimens. Casein blocking can reduce the false-positive rates, but at the same time it resulted in some cases classified as ER-negative despite true ER staining using the standard validated staining techniques. ER antibody clones used showed no difference in staining sensitivity and specificity in the detection of ER-low-positive tumors.

At the molecular level, neither *ESR1* mRNA levels nor molecular subtyping were significantly different between ER-negative and ER 1%-9% groups. This indicates that the ER 1%-9% cases at the IHC level may not represent a truly ER-positive BC, and intermingled ER-negative cases are the reason for molecular resemblance. On the contrary, ER 10%-19% cases had significantly higher tendency as being classified as luminal types with higher *ESR1* mRNA levels.

Pathologists tend to round scores, so a score of 10% may be more frequent than scores around this figure, when convincing staining is present. Consequently, we analyzed tumors expressing ER 10%, which were associated with favorable parameters compared with ER-low-positive tumors. Cases with exactly 10% ER positivity seemed to differ from ER-negative and ER-low groups (1%-9%). A study showed that 75% of ER-positive tumors with 10% positivity were of the luminal A molecular subtype.[9] Based on a

similar response of ER 1%-9% patients to ER-negative patients who received either neoadjuvant or adjuvant chemotherapy in previous studies, 10% was used to define ER-positive BC.[37,38] Additionally, BC patients with ER 1%-10% showed better DMFS and DFS compared with ER-negative BC patients, whereas ER 1%-9% tumors did not show any difference. It seems that adding 10% was the key parameter in this statistical difference, which supports that a 10% ER score should be regarded as positive BC. Therefore, our results suggest that 10% would be a more reliable cutoff rather than the 1% currently proposed by ASCO/CAP.

The outcome of ER-low BC is variable between studies. In a recent clinical trial, there was a significant difference between survival in patients with ER-low-positive and positive BC with the former showing inferior outcome, which was not observed when ER-low-positive cases were compared with ER-negative cases.[36] This was consistent with our study. Similar results were reported in a meta-analysis conducted on 11 different studies.[2,9,10,14,33,38-43] Better outcome in ER-low-positive tumors compared with ER-negative tumors has been further documented; however, these studies had limited case numbers.[13,18]

Response to ET in ER-low-positive BC is of crucial clinical significance. However, available data are limited, and most studies conducted were retrospective due to the rarity of this group. A few studies reported benefits from ET in ER-low-positive patients; however, the use of different scoring methods and cutoffs combined with limited follow-up make such results less reliable.[18,44,45] A systematic review and meta-analysis included 6 studies on the benefit of ET in ER-low-positive BC but did not find significant survival benefit, although it suggested a better prognosis than in case of ER-negative tumors.[7] The scoring method of these studies was variable, using either the Allred score[46] or combined ER/PR scores.[14] Landmann et al[10] reported that ER-low-positive BCs achieved similar pathological complete response rates as ER-negative tumors, which were significantly different from ER-positive tumors. It was suggested that ER-low-positive BCs should be treated as ER-negative BCs, rather than ER-positive tumors, based on their similarity to ER-negative BC in response to neoadjuvant chemotherapy.[39] A prospective study on the benefit of patients with ER-low-positive BC from ET found better DFS after 5 years of tamoxifen.[15] The latest ASCO/CAP guidelines recommend a discussion with patients diagnosed with ER-low-positive BCs particularly as there are limited data on ET benefit.[11] The small number of patients with ER-low-positive BC who received ET in addition to the censoring limitations restricted our survival analysis.

Although a strong concordance of ER status between NCB and surgical excision specimen was reported,[47,48] with less than 1% of cases being reassigned from ER-positive to ER-negative (5 out of 1249[49], and 4 out of 465[50]), spatial heterogeneity in different tumor areas[51] could account for the difference in ER status reported in NCB and excision specimens, which has been reported to range from 6% to 17%.[49,50,52] In a previous concordance study of 806 NCBs and the corresponding surgical excision specimens,[53] only 1 ER-positive case in NCB (>10%) was subsequently reassigned to ER-negative on the excision specimen. In contrast to this, analysis of 23 ER-low-positive cases revealed that 11 (48%) were consistently assigned as ER-low in NCB and excision specimens, whereas 8 cases (35%) were reassigned to ER-negative, and 4 cases (17%) were reassigned to ER-positive. These results are consistent with our results and demonstrate the importance of repeat staining of tumors with low-positive ER status.

Using percentages as a cutoff is complicated by variation in tumor sampling and cellularity in core biopsies particularly in the low ER expression cases. Repeating the staining on the excisional

specimens of cases reported as ER 1%-9% in original NCBs will also allow a more accurate assessment and categorization of these cases where more tumor tissue is represented to overcome the heterogeneity and "denominator" effects.

Previous studies reported a significantly lower mean of ER expression in excisional specimens compared with NCB, especially in the ER-low group, due to better fixation.[54,55] Adequate fixation of the excision specimen is essential to obtain reliable results. In our institution, a cruciate incision through excisional breast specimens is routinely carried out to ensure proper immediate fixation, and proper internal and external controls are applied for each case. If fixation is suboptimal, the results of the core biopsy can be considered and a statement to highlight the limitation of the final results should be included in the pathology report.

Although methods for *ESR1* mRNA detection could be beneficial in these cases, reproducibility can be influenced by different RNA extraction assays, reagent, and probes selectivity, PCR protocols, and RNA integrity. Contamination with nonmalignant cells during RNA extraction is an additional potential cause of false negativity.[56] Thus, IHC remains the method of choice for ER testing.[11]

High concordance in assessment of ER staining as either ER-positive/negative is reported;[6,57] however, Reisenbichler et al[58] showed discrepancy of ER scoring in ER-low-positive tumors. Only moderate agreement was revealed, and the majority of the discrepant cases showed very weak-to-weak intensities. Unlike a previous study[18] that showed that all ER-low-positive cases were weak, we found a few cases with moderate and strong intensities. This is noteworthy as the Allred score of 3 previously recommended by Harvey and colleagues representing 1%-10% of weak positive cells, can also represent <1% of cells with moderate or strong intensity.[6,58] The tumor cells showing nuclear expression are defined as positive regardless of staining intensity, however, Caruana et al[31] argued that the low ER positivity seen in this group originated from low staining intensity. They examined the adjacent normal breast ducts and compared them to normal ducts in control cases, to find that they have lower intensity and suggested repeating IHC staining even in the presence of positive internal control.[31] The recent ASCO/CAP updates recommended the inclusion of external positive control with known low ER expression such as tonsil and cervix as a quality assurance step while assessing ER expression in BC, especially the low-expressing tumors.[11]

We previously reported nuclear-staining granularity with the 6F11 anti-ER antibody.[59] However, in the present study, this punctate staining was also detected in SP1 and EP1 antibodies. When we compared cases stained with both antibodies, there was a high correlation between them, which addresses the concerns regarding the high sensitivity of SP1 leading to misclassification of some very low ER-expressing BCs as ER-positive.[60]

We also found that more than half of the ER-low-positive cases had nonspecific staining either stromal, cytoplasmic, or both. False interpretation of nonspecific staining may explain the interobserver discordance reported in this group. Casein block has been used to reduce nonspecific staining.[61] The interpathologist agreement was improved on the cases that were stained using casein blocking, however, some cells lost their true nuclear positivity.[62] Therefore, we do not recommend using casein block during ER IHC staining.

ASCO/CAP recommends consideration of image analysis to validate the results of ER-low expression;[11] however, no defined scoring criteria were recommended. There was only moderate agreement between our visual assessment and digital scores, suggesting that image analysis is not the key to improving concordance in ER-low-positive scoring. We noted that positive cell detection was overestimated in cases of nonspecific/background staining, which makes its reliability questionable. The threshold of intensity at which the cells would be detected s positive, is controllable, however, the scoring of weakly stained cells would still be subjective depending on the threshold. A recent study on quantitative image analysis on a large number of ER cases showed strong agreement with the pathologist's score but most discordant cases were in the ER-low-positive category.[63]

In conclusion, ER-low-positive BCs (1%-9%) have pathological features and outcome more similar to ER-negative tumors than those with stronger ER expression. Our data suggest that 10% ER positivity should be regarded as true ER-positive BC. Repeat staining on excisional specimens is advised in all ER-low tumors identified in NCB. Weak granular ER staining should be interpreted with caution, and we recommend reporting this may represent a false-positive result. Image analysis in ER-low-positive BC is not superior to the visual estimates and should be used cautiously.

Declaration of Competing Interest

The authors have declared no conflicts of interest.

Ethics Approval and Consent to Participate

This study was approved by the Yorkshire and the Humber — Leeds East Research Ethics Committee (REC Reference: 19/YH/0293) under the IRAS Project ID: 266925. All patients were consented. Data collected was fully anonymized. All procedures performed in the study were in accordance with the Declaration of Helsinki.

Supplementary Material

The online version contains supplementary material available at https://doi.org/10.1016/j.modpat.2023.100284

References

1. Dodson A, Parry S, Ibrahim M, et al. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199300 patients. *J Pathol.* 2018;4(4):262−273. https://doi.org/10.1002/cjp2.112
2. Zhang Z, Wang J, Skinner KA, et al. Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. *Histopathology.* 2014;65(4):508−516. https://doi.org/10.1111/his.12412
3. Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Archiv Pathol Lab Med.* 2010;134(7):e48−e72. https://doi.org/10.5858/134.7.e48
4. Guidelines Working Group of the UK National Coordinating Committee for Breast Pathology. *Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer.* The Royal College of Pathologists; June. 2016:160.
5. Brouckaert O, Paridaens R, Floris G, Rakha E, Osborne K, Neven P. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. *Ann Oncol.* 2013;24(1):47−53. https://doi.org/10.1093/annonc/mds238
6. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol.* 1999;17(5):1474−1481. https://doi.org/10.1200/JCO.1999.17.5.1474
7. Chen T, Zhang N, Moran MS, Su P, Haffty BG, Yang Q. Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis. *Clin Breast Cancer.* 2018;18(1):1−8. https://doi.org/10.1016/j.clbc.2017.06.005
8. Davies C, Godwin J, Gray R, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet.* 2011;378(9793):771−784. https://doi.org/10.1016/S0140-6736(11)60993-8
9. Deyarmin B, Kane JL, Valente AL, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. *Ann Surg Oncol.* 2013;20(1):87−93. https://doi.org/10.1245/s10434-012-2588-8
10. Landmann A, Farrugia DJ, Zhu L, et al. Low estrogen receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: Is response similar to typical ER-positive or ER-negative disease? *Am J Clin Pathol.* 2018;150(1):34−42. https://doi.org/10.1093/ajcp/aqy028
11. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. *J Clin Oncol.* 2020;38(12):1346−1366. https://doi.org/10.1200/JCO.19.02309
12. Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. *Ann Oncol.* 2021;32(11):1410−1424. https://doi.org/10.1016/j.annonc.2021.08.1988
13. Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. *J Clin Oncol.* 2012;30(7):729−734. https://doi.org/10.1200/JCO.2011.36.2574
14. Balduzzi A, Bagnardi V, Rotmensz N, et al. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. *Clin Breast Cancer.* 2014;14(4):258−264. https://doi.org/10.1016/j.clbc.2013.10.019
15. Cai YW, Shao ZM, Yu KD. De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: propensity-matched analysis from a prospectively maintained cohort. *Cancer.* 2022;128(9):1748−1756. https://doi.org/10.1002/cncr.34155
16. Park YH, Karantza V, Calhoun SR, et al. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. *Breast Cancer Res Treat.* 2021;189(3):653−663. https://doi.org/10.1007/s10549-021-06309-1
17. Raghav KP, Hernandez-Aya LF, Lei X, et al. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. *Cancer.* 2012;118(6):1498−1506. https://doi.org/10.1002/cncr.26431
18. Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. *Breast Cancer Res Treat.* 2021;188(1):225−235. https://doi.org/10.1007/s10549-021-06148-0
19. Lashen AG, Toss MS, Katayama A, Gogna R, Mongan NP, Rakha EA. Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study. *Histopathology.* 2021;79(6):1087−1098. https://doi.org/10.1111/his.14542
20. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Arch Pathol Lab Med.* 2007;131(1):18−43. https://doi.org/10.5858/2007-131-18-ASOCCO
21. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. *Histopathology.* 2005;46(6):685−693. https://doi.org/10.1111/j.1365-2559.2005.02156.x
22. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clin Cancer Res.* 2009;15(7):2302−2310. https://doi.org/10.1158/1078-0432.Ccr-08-2132
23. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. *J Clin Oncol.* 2007;25(30):4772−4778. https://doi.org/10.1200/JCO.2007.12.2747
24. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. *J Clin Oncol.* 2008;26(19):3153−3158. https://doi.org/10.1200/JCO.2007.15.5986
25. Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J Mol Diagn.* 2012;14(1):22−29. https://doi.org/10.1016/j.jmoldx.2011.08.002
26. Shi J, Liu H, Ma X-J, et al. Ribonucleic acid in situ hybridization is a more sensitive method than immunohistochemistry in detection of thyroid transcription factor 1 and napsin A expression in lung adenocarcinomas. *Arch Pathol Lab Med.* 2016;140(4):332−340. https://doi.org/10.5858/arpa.2014-0644-OA
27. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. *Nat Protoc.* 2008;3(6):1101−1108. https://doi.org/10.1038/nprot.2008.73
28. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. *Sci Rep.* 2017/12/04 2017;7(1), 16878. https://doi.org/10.1038/s41598-017-17204-5
29. Berben L, Wildiers H, Marcelis L, et al. Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. *Histopathology.* 2020;77(1):79−91. https://doi.org/10.1111/his.14108
30. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. *Am J Clin Pathol.* 2005;123(1):21−27. https://doi.org/10.1309/4wv79n2ghj3x1841
31. Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. *NPJ Breast Cancer.* 2020;6(1):1−6. https://doi.org/10.1038/s41523-020-0146-2
32. Gloyeske NC, Dabbs DJ, Bhargava R. Low ER+ breast cancer: is this a distinct group? *Am J Clin Pathol.* 2014;141(5):697−701. https://doi.org/10.1309/AJCP34CYSATWFDPQ
33. Yi M, Huo L, Koenig K, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. *Ann Oncol.* 2014;25(5):1004−1011. https://doi.org/10.1093/annonc/mdu053
34. Yu KD, Cai YW, Wu SY, Shui RH, Shao ZM. Estrogen receptor-low breast cancer: biology chaos and treatment paradox. *Cancer Commun.* 2021;41(10):968−980. https://doi.org/10.1002/cac2.12191
35. Kuroda H, Muroi N, Hayashi M, et al. Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining. *Breast Cancer.* 2019;26(2):249−254. https://doi.org/10.1007/s12282-018-0898-9
36. Villegas SL, Nekljudova V, Pfarr N, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors−an analysis of 2765 patients from neoadjuvant clinical trials. *Eur J Cancer.* 2021;148:159−170. https://doi.org/10.1016/j.ejca.2021.02.020
37. Dieci MV, Griguolo G, Bottosso M, et al. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. *NPJ Breast Cancer.* 2021;7(1):107. https://doi.org/10.1038/s41523-021-00308-7
38. Fujii T, Kogawa T, Dong W, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. *Ann Oncol.* 2017;28(10):2420−2428. https://doi.org/10.1093/annonc/mdx397
39. Paakkola N-M, Karakatsanis A, Mauri D, Foukakis T, Valachis A. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. *ESMO Open.* 2021;6(6):100289. https://doi.org/10.1016/j.esmoop.2021.100289
40. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. *Clin Cancer Res.* 2004;10(19):6622−6628. https://doi.org/10.1158/1078-0432.CCR-04-0380
41. Ding Y, Ding K, Yu K, et al. Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: a retrospective study of 570 patients in China. *Oncol Lett.* 2019;18(6):6690−6696. https://doi.org/10.3892/ol.2019.11033

42. Ohara AM, Naoi Y, Shimazu K, et al. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. *Breast Cancer Res Treat*. 2019;173(3):533–543. https://doi.org/10.1007/s10549-018-5020-7

43. Prabhu JS, Korlimarla A, Desai K, et al. A majority of low (1–10%) ER positive breast cancers behave like hormone receptor negative tumors. *J Cancer*. 2014;5(2):156. https://doi.org/10.7150/jca.7668

44. Bouchard-Fortier A, Provencher L, Blanchette C, Diorio C. Prognostic and predictive value of low estrogen receptor expression in breast cancer. *Curr Oncol*. 2017;24(2):106–114. https://doi.org/10.3747/co.24.3238

45. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. *J Clin Oncol*. 2007;25(25): 3846–3852. https://doi.org/10.1200/JCO.2007.11.9453

46. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. *Breast Cancer*. 2004;11(3):267–275. https://doi.org/10.1007/BF02984548

47. Ambrosini-Spaltro A, Zunarelli E, Bettelli S, et al. Surrogate molecular classification of invasive breast carcinoma: a comparison between core needle biopsy and surgical excision, with and without neoadjuvant therapy. *Appl Immunohistochem Mol Morphol*. 2020;28(7):551–557. https://doi.org/10.1097/pai.0000000000000797

48. Chen X, Sun L, Mao Y, et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. *BMC Cancer*. 2013;13:390. https://doi.org/10.1186/1471-2407-13-390

49. Pölcher M, Braun M, Tischitz M, et al. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. *Arch Gynecol Obstet*. 2021;304(3):783–790. https://doi.org/10.1007/s00404-021-05996-x

50. Robertson S, Rönnlund C, de Boniface J, Hartman J. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. *Breast Cancer Res Treat*. 2019;174(3):795–805. https://doi.org/10.1007/s10549-018-05119-2

51. Fumagalli C, Barberis M. Breast cancer heterogeneity. *Diagnostics*. 2021;11(9):1555. https://doi.org/10.3390/diagnostics11091555

52. Shanmugalingam A, Hitos K, Hegde S, et al. Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers. *Breast Cancer Res Treat*. 2022;193(1):151–159. https://doi.org/10.1007/s10549-022-06548-w

53. Rossi C, Fraticelli S, Fanizza M, et al. Concordance of immunohistochemistry for predictive and prognostic factors in breast cancer between biopsy and surgical excision: a single-centre experience and review of the literature. *Breast Cancer Res Treat*. 2023;198(3):573–582. https://doi.org/10.1007/s10549-023-06872-9

54. Hodi Z, Chakrabarti J, Lee AH, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. *J Clin Pathol*. 2007;60(3):299–302. https://doi.org/10.1136/jcp.2006.036665

55. Clark BZ, Onisko A, Assylbekova B, et al. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. *Mod Pathol*. 2019;32(3):354–366. https://doi.org/10.1038/s41379-018-0153-0

56. Dekker T, Ter Borg S, Hooijer G, et al. Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. *Breast Cancer Res Treat*. 2015;152(2):247–252. https://doi.org/10.1007/s10549-015-3444-x

57. Allred D, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol*. 1998;11(2): 155–168. PMID 9504686.

58. Reisenbichler ES, Lester SC, Richardson AL, Dillon DA, Ly A, Brock JE. Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. *Am J Clin Pathol*. 2013;140(4):487–494. https://doi.org/10.1309/AJCP1RF9FUIZRDPI

59. Rakha EA, Lee A, Roberts J, et al. Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. *J Clin Oncol*. 2012;30(23):2929–2930. https://doi.org/10.1200/JCO.2012.43.2831

60. Troxell ML, Long T, Hornick JL, Ambaye AB, Jensen KC. Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data. *Arch Pathol Lab Med*. 2017;141(10):1402–1412. https://doi.org/10.5858/arpa.2016-0497-OA

61. Buchwalow I, Samoilova V, Boecker W, Tiemann M. Non-specific binding of antibodies in immunohistochemistry: fakes and facts. *Nat Precedings*. 2011;1: 1. https://doi.org/10.1038/npre.2011.5892.1

62. Hasui K, Murata F. A new simplified catalyzed signal amplification system for minimizing non-specific staining in tissues with supersensitive immunohistochemistry. *Arch Histol Cytol*. 2005;68(1):1–17. https://doi.org/10.1679/aohc.68.1

63. Yousif M, Huang Y, Sciallis A, et al. Quantitative image analysis as an adjunct to manual scoring of ER, PgR, and HER2 in invasive breast carcinoma. *Am J Clin Pathol*. 2022;157(6):899–907. https://doi.org/10.1093/ajcp/aqab206